Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single-Center Study.

Cancer Med · 2026 · PMC13099366 · PMID 42014920

Europe PMC DOI

hedged sentences

0.2040

closest p · 4.1× alpha

0.2040

boldest claim

The sentences

showed a trendp = 0.204not close (p > 0.1)

14.3%, p = 0.027) and showed a trend toward higher ORR compared to RCTS (68.8% vs. 37.5%, p = 0.204).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

14.3%, p = 0.108), although these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.